𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease

✍ Scribed by L. Verhagen Metman; P. Del Dotto; P. J. Blanchet; P. van den Munckhof; T. N. Chase

Publisher
Springer
Year
1998
Tongue
English
Weight
566 KB
Volume
14
Category
Article
ISSN
0939-4451

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Quality of life in early Parkinson's dis
Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations
✍ Connie Marras; Anthony Lang; Murray Krahn; George Tomlinson; Gary Naglie πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 80 KB πŸ‘ 1 views

## Abstract The impact of dyskinesias and motor fluctuations on quality of life (QOL) at various stages in the course of Parkinson's disease (PD) is not well understood. In 301 subjects with early PD enrolled in a clinical trial (CALM‐PD), we quantified the impact of motor complications on QOL and

Motor response to levodopa and the evolu
Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease
✍ Craig D. McColl; Katrina A. Reardon; Mark Shiff; Peter A. Kempster πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 935 KB

Thirty-four patients with Parkinson's disease were followed for a mean period of 8 years from the time of initiation of levodopa medication. Levodopa response was charted from the starting point of pharmacological treatment to give a longitudinal point of view of the changes that evolve as the disea

Sarizotan as a treatment for dyskinesias
Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial
✍ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 117 KB πŸ‘ 1 views

## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio